Myomo (MYO) Net Cash Flow Growth (3y) (2019 - 2025)
Myomo (MYO) Net Cash Flow Growth (3y) (2019 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 202.72 Bn | 197.12 Bn | 7.27 Bn | -9.45% |
| 2 | Stryker | 126.42 Bn | 122.94 Bn | 4.50 Bn | 60.16% |
| 3 | Medtronic | 119.75 Bn | 110.53 Bn | 6.41 Bn | 31.32% |
| 4 | Boston Scientific | 74.13 Bn | 73.60 Bn | 3.85 Bn | -85.83% |
| 5 | Edwards Lifesciences | 51.78 Bn | 47.53 Bn | 1.35 Bn | 43.26% |
| 6 | Dexcom | 35.29 Bn | 33.34 Bn | 830.00 Mn | -26.30% |
| 7 | GE HealthCare Technologies | 33.95 Bn | 31.85 Bn | 2.18 Bn | 21.48% |
| 8 | Koninklijke Philips | 26.22 Bn | 22.90 Bn | 4.55 Bn | -127.77% |
| 9 | Steris | 23.21 Bn | 22.73 Bn | 684.20 Mn | 269.22% |
| 10 | Myomo | 67.26 Mn | 48.29 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 15.55% |
| Jun 30, 2025 | -27.69% |
| Mar 31, 2025 | -21.48% |
| Dec 31, 2024 | 82.47% |
| Sep 30, 2024 | 43.75% |
| Jun 30, 2024 | 28.37% |
| Mar 31, 2024 | -31.58% |
| Dec 31, 2023 | 62.15% |
| Sep 30, 2023 | -28.95% |
| Jun 30, 2023 | -2.86% |
| Mar 31, 2023 | -24.98% |
| Dec 31, 2022 | -158.38% |
| Sep 30, 2022 | -6.21% |
| Jun 30, 2022 | -1.74% |
| Mar 31, 2022 | -43.50% |
| Dec 31, 2021 | 46.54% |
| Sep 30, 2021 | 23.36% |
| Jun 30, 2021 | -14.30% |
| Mar 31, 2021 | 64.29% |
| Dec 31, 2020 | -28.89% |